Publikace na Lékařská fakulta v Plzni |
2024
Abstrakt
The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive pathways and impeding tumour evasion.
This synergy with pembrolizumab shows potential in enhancing immunotherapy for these patients.